This document is developed using technical input from the Interim Guidance on Scaling-up COVID-19 Outbreak in Readiness and Response Operations in Camps and Camp-like Settings and Key Considerations for Selecting Health Infrastructure for the Response to COVID 19 in addition to other tec...hnical guidance documents developed by WHO and referenced accordingly.
more
13 April 2021 Policy Brief
Rev Méd Hondur, Vol 88, Núm 2, 202
What is Violence Against Women? Why does it happen? What does it have to do with development? What does Oxfam do to end violence against women? What does it mean to do that work with a transformative approach?
Available in: English, Arabic, French, Spanish: https://policy-practice.oxfam.org.uk/publ...ications/ending-violence-against-women-an-oxfam-guide-254118
more
Towards gender - transformative HIV and TB responses
Combined questionnaire Core
2nd edition. This new edition provides policy-makers, programme managers and health-service providers with the latest evidence-based guidance on clinical care. It includes information on how to establish and strengthen services, and outlines a human-rights-based approach to laws and policies on safe..., comprehensive abortion care. This guidelines is available in English; French, Spanish; Japanese; Russian; Portuguese; Romanian and Ukrainian
more
This policy brief is targeted at national governments, donors and regional and international actors to support Ebola-affected countries to transition from emergency response to recovery.
Informe Conjunto de Organizaciones de Defensa del Derecho a la Salud al Comité de Derechos Económicos y Sociales de las Naciones Unidas, con motivo del Examen del 3er Informe Periódico del Estado Venezolano en el Período de Sesión 55° del Pacto Internacional de Derechos Económicos, Sociales y... Culturales
more
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...G ne soit pas apparue dans les populations naïves aux TAR incapables
de supprimer la charge virale dans les essais cliniques, certains éléments portent à croire que la résistance au
DTG peut émerger chez les personnes suivant des schémas thérapeutiques incluant le DTG. L’OMS recommande aux
pays qui étendent les TAR incluant le DTG d’accompagner ce déploiement d’une surveillance en routine de la pharmacorésistance
more